CooperVision Highlights Evidence-Based Contact Lens Innovation at 2026 Netherlands Contact Lens Congress
Key Takeaways
CooperVision will present new research at the 2026 Netherlands Contact Lens Congress showing how evidence-based innovation can support comfortable, high-quality contact lens wear from first fit through presbyopia
Studies highlight wearer experiences across multiple stages of life, including adaptation to MiSight 1 day for myopia control and continued strong performance of modern spherical lenses such as MyDay, Biofinity, and Biofinity Energys
Additional research explores practitioner prescribing patterns, multifocal lens fitting opportunities for early presbyopes, and insights into consumer attitudes toward remote eye care and contact lens adoption
CooperVision will present a range of scientific papers and posters in the British Contact Lens Association (BCLA) scientific stream at the 2026 Netherlands Contact Lens Congress (NCC), demonstrating how evidence-based care and ongoing innovation can support clear, comfortable contact lens wear across every stage of life. The conference takes place March 8–9 in Veldhoven, Netherlands, bringing together eye care professionals, researchers, and industry leaders from around the world.
“The research we are sharing at NCC drives better understanding of wearer satisfaction, new fit adaptation, and prescribing patterns. These insights help eye care professionals confidently support patients from their very first contact lens experience through presbyopia," said Marcella McParland, MCOptom, FAAO, FIACLE, FBCLA, Senior Director, Professional Affairs, EMEA, CooperVision.
Among the research highlights is an investigator-initiated paper examining the transition from a single-vision contact lens to the dual-focus design of MiSight 1 day for myopia control. The study found that young adults report comparable vision quality and comfort within 6 months of the transition. The findings emphasize the importance of practitioners setting appropriate expectations around comfort and visual performance during the adaptation period.
Addressing a broader patient population, another paper validates that modern spherical contact lens designs—including MyDay, Biofinity, and Biofinity Energys brand—continue to meet the everyday needs of both new and experienced wearers. The research highlights strong performance in areas such as comfort, vision quality, and overall satisfaction.
CooperVision will also present posters exploring emerging trends in eye care delivery and patient behavior. These include comparisons of practitioner and consumer perspectives on remote eye care, as well as insights into motivations and decision-making among new and lapsed contact lens wearers, identifying opportunities to increase trial and adoption.
Further along the wear continuum, additional CooperVision-supported research on multifocal contact lenses will be showcased at NCC. One study suggests opportunities for more proactive fitting for early presbyopic patients and closer adherence to recommended fitting guides. Other studies highlight encouraging satisfaction rates among hydrogel multifocal wearers refit into silicone hydrogel materials, as well as both new and habitual contact lens wearers fitted into multifocal lenses for the first time.
More information about the studies is available through the Abstracts 2026 – Nederlands Contactlens Congres. Held biennially, the NCC attracts thousands of eye care professionals, educators, researchers, and manufacturers from the Netherlands, across Europe, and globally. Details about the 2026 sessions and speakers can be found at contactlenscongress.com.
Originally published online on Eyewire+.